LENZ 📈 LENZ Therapeutics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
LENZ: Eye, Drops, Medication, Presbyopia, Treatment
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. Web URL: https://www.lenz-tx.com
Additional Sources for LENZ Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LENZ Stock Overview
| Market Cap in USD | 600m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2021-06-25 |
LENZ Stock Ratings
| Growth 5y | 51.8% |
| Fundamental | 1.33% |
| Dividend | 25.2% |
| Rel. Strength Industry | - |
| Analysts | 4.57/5 |
| Fair Price Momentum | 28.68 USD |
| Fair Price DCF | - |
LENZ Dividends
| Dividend Yield 12m | 3.57% |
| Yield on Cost 5y | 8.23% |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 100.0% |
LENZ Growth Ratios
| Growth Correlation 3m | 63.8% |
| Growth Correlation 12m | 93.9% |
| Growth Correlation 5y | 15.4% |
| CAGR 5y | 26.77% |
| CAGR/Mean DD 5y | 0.41 |
| Sharpe Ratio 12m | 1.14 |
| Alpha | 941.57 |
| Beta | 2.39 |
| Volatility | 82.20% |
| Current Volume | 117.6k |
| Average Volume 20d | 159.1k |
What is the price of LENZ stocks?
As of January 02, 2025, the stock is trading at USD 28.87 with a total of 117,600 shares traded.
Over the past week, the price has changed by -9.81%, over one month by -22.75%, over three months by +26.62% and over the past year by +1517.46%.
As of January 02, 2025, the stock is trading at USD 28.87 with a total of 117,600 shares traded.
Over the past week, the price has changed by -9.81%, over one month by -22.75%, over three months by +26.62% and over the past year by +1517.46%.
Is LENZ Therapeutics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, LENZ Therapeutics is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 1.33 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LENZ as of January 2025 is 28.68. This means that LENZ is currently overvalued and has a potential downside of -0.66%.
Neither. Based on ValueRay Fundamental Analyses, LENZ Therapeutics is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 1.33 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LENZ as of January 2025 is 28.68. This means that LENZ is currently overvalued and has a potential downside of -0.66%.
Is LENZ a buy, sell or hold?
LENZ Therapeutics has received a consensus analysts rating of 4.57. Therefor, it is recommend to buy LENZ.
LENZ Therapeutics has received a consensus analysts rating of 4.57. Therefor, it is recommend to buy LENZ.
- Strong Buy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for LENZ stock price target?
According to ValueRays Forecast Model, LENZ LENZ Therapeutics will be worth about 33.3 in January 2026. The stock is currently trading at 28.87. This means that the stock has a potential upside of +15.28%.
According to ValueRays Forecast Model, LENZ LENZ Therapeutics will be worth about 33.3 in January 2026. The stock is currently trading at 28.87. This means that the stock has a potential upside of +15.28%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 33.8 | 17.1% |
| Analysts Target Price | 34 | 17.8% |
| ValueRay Target Price | 33.3 | 15.3% |